RCS - Berlin Cures Holding - Personnel/Research Update
29/08/2024 08:30
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240829:nRSc1402Ca&default-theme=true RNS Number : 1402C Berlin Cures Holding AG 29 August 2024 Issuer: Berlin Cures Holding AG / Key word(s): Personnel/Research Update Berlin Cures Welcomes Renowned Immunologist Professor Danny Altmann to its Advisory Board 29.08.2024 The issuer is solely responsible for the content of this announcement. Berlin, Germany, 29 August 2024 - Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment against Long COVID and other autoimmune diseases, is pleased to announce the appointment of Professor Danny Altmann to its Advisory Board. Altmann, a distinguished immunologist from the Imperial College London, will bring invaluable expertise to the company's drug research and development efforts focused on autoimmune diseases, including Long COVID. The role of the Advisory Board is to advise Berlin Cures on industry developments, explore growth opportunities, and support the successful market launch of new therapies. "We are thrilled to welcome Professor Altmann to our Advisory Board," said Oliver von Stein, CEO of Berlin Cures. "His extensive experience and highly regarded research in immunology, particularly related to the long-term effects of SARS-CoV-2, make him the perfect addition to our esteemed Advisory Board. I'm confident that his guidance will be of great value in our efforts to develop and bring to market effective treatments for Long COVID and other diseases associated with functional autoantibodies." Danny Altmann is a Professor of Immunology at Imperial College London, where he leads a laboratory at the Hammersmith Hospital campus. Throughout the COVID-19 pandemic, Altmann played a key advisory role to various policy makers and organizations, including the House of Commons and House of Lords Science Committees, the EU, the Scottish Parliament, the World Health Organisation and many others. He is currently heading a research project to understand the long-term immunological effects of SARS-CoV-2, is a trustee at the British organization Long COVID support and has co-authored the Penguin Long COVID Handbook. Berlin Cures, a biotechnology company specializing in the neutralization of functional autoantibodies (fAABs), is currently conducting a Phase II clinical trial with its drug candidate BC 007 (Rovunaptabin) in patients with Long COVID. Initial results are expected in Q4 2024. Berlin Cures has already completed a Phase IIa study with BC 007 in heart failure, showing long-term neutralization of functional autoantibodies after a single dose. Berlin Cures is currently actively seeking financial partners to fund a potential Phase III trial as soon as possible after a positive Phase II outcome. A subsequent successful Phase III trial would be the prerequisite for obtaining market approval for BC 007. Biographies of Danny Altmann and further Advisory Board members can be found here (https://www.berlincures.com/en/about#cblock_467) . About Berlin Cures: The Berlin Cures team has dedicated over two decades to the research of functional autoantibodies (fAABs) and has successfully identified a molecule capable of effectively neutralizing these. Promising preclinical results have been observed for BC 007. In a recently completed Phase IIa trial with patients with chronic heart failure, BC 007 demonstrated long-term autoantibody neutralization after a single dose resulting in significant improvement in cardiac function. Its potential as an effective therapy for Long COVID was realized when tests on sera from Long COVID patients proved positive for fAABs, supported by clinical observations in four case studies. By addressing the underlying cause of fAAB-associated diseases with this unique biotechnology, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue at its core. Berlin Cures is currently running a Phase II clinical trial with BC 007 in the indication Long COVID, an acute and escalating global health problem, to obtain meaningful and robust results on efficacy and tolerability. The trial is fully recruited, and first results are expected in Q4 2024. Contact: FGS Global E-Mail: berlincures-eu@fgsglobal.com (mailto:berlincures-eu@fgsglobal.com) Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com (//www.eqs-news.com) This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NRAQKLBLZVLFBBE